



JNK Inhibitor II (SP 600125)

anthra(1,9-*cd*)pyrazol-6(2*H*)-one

PRODUCT ANALYSIS SHEET

Catalog Number: PHZ1064

Lot Number: See product label

Quantity: 5.0 mg

Appearance: Yellow-brown solid

Molecular Formula: C₁₄H₈N₂O

Molecular Weight: 220.2

Purity: ≥98%, as determined by HPLC

Summary: SP 600125 is a cell-permeable, potent, reversible inhibitor of c-Jun N-terminal kinase (JNK), and is a valuable tool for elucidating the role of JNK in chronic inflammatory diseases, apoptosis, and cell proliferation. Kinetic studies indicate that SP 600125 is competitive with respect to ATP. This compound impacts transcription profiles by inhibiting the phosphorylation of c-Jun, a component of the AP-1 transcription factor. The expression of several key signaling proteins, including COX-2, IL-2, IFN- γ , and TNF- α , is blocked by this compound.

Biological Activity: JNK1: IC₅₀ = 40 nM

JNK2: IC₅₀ = 40 nM

JNK3: IC₅₀ = 90 nM

Solubility: Soluble in DMSO at a concentration of 15 mg/mL.

Suggestions for Use: SP 600125 is only slightly soluble in aqueous media. To ensure delivery to cells, media to which SP 600125 will be added can be supplemented with 0.1% DMSO. Solubility can also be enhanced by supplementing media with serum proteins, then warming the media prior to SP 600125 addition.

Sterility: This product is not sterile.

Storage: Store, as supplied, at -20°C, protected from light. Upon solubilization, apportion into working aliquots, flush with an inert gas, and store at -20°C. Solutions are stable at -20°C for up to two months.

Expiration Date: Expires one year from date of receipt when stored as instructed.

Related Products: JNK [pTpY183/185] antibody, Cat. # 44-682G c-Jun antibody, Cat. # AHO1002
p38 [pTpY 180/182] antibody, Cat. # 44-684G ERK1/2 [pTpY185/187] antibody, Cat. # 44-680G

References: Bennett, B.L., D.T. Sasaki, B.W. Murray, E.C. O'Leary, S.T. Sakata, W. Xu, J.C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S.S. Bhagwat, A.M. Manning, and D.W. Anderson (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. *Proc. Nat'l. Acad. Sci.* 98(24):13681-13686.

Han, Z., D.L. Boyle, L. Chang, B. Bennett, M. Karin, L. Yang, A.M. Manning, and G.S. Firestein (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. *J. Clin. Invest.* 108(2):181-183.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI PHZ1064

(Rev 2.0) DCC-08-1232

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

diagnostic, therapeutic or commercial use.



Caution:

Avoid contact with eyes, skin, and mucous membranes. Wear protective clothing when handling this product. Not for human use.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI PHZ1064

(Rev 2.0) DCC-08-1232

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

